Tivdak
FDA Fully Approves Tivdak for Recurrent or Metastatic Cervical Cancer
The FDA has granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen [now part of Pfizer]) for ...
MAY 1, 2024
In Recurrent/Metastatic Cervical Cancer, Tisotumab Vedotin Improves Survival
In patients with recurrent or metastatic cervical cancer, treatment with the antibody–drug conjugate ...
NOVEMBER 6, 2023
FDA Approves Tivdak for Recurrent or Metastatic Cervical Cancer
The FDA granted accelerated approval to tisotumab vedotin-tftv (Tivdak, Seagen/Genmab), a tissue ...
SEPTEMBER 24, 2021
Load more